The Chemours Company (NYSE:CC) of the Chemicals sector might have recently popped up on investor’s radars as the 5746738 market cap company based out of United States of America recently closed at 33.590000.  The stock has seen year over year sales growth of 0.13811 giving it a traded value of $54188.

Investors are constantly on the lookout for that next great stock pick. Finding that particular stock that had been overlooked by the rest of the investing community can bring great satisfaction to the individual investor. Spotting these stocks may take a lot of time and effort, but the rewards may be well worth it. Knowledge is power, and this principle also translates over to the equity market. Investors who are able to dig a little bit deeper may be setting themselves up for much greater success in the long run. These days, investors have access to a wide range of information. Trying to filter out the important information can be a key factor in portfolio strength. Knowing what data to look for and how to trade that information is extremely important. Successful investors are typically able to focus their energy on the right information and then apply it to a trading strategy. 

So how has The Chemours Company (NYSE:CC) performed in terms of returns?  The ROIC quality score stands at 5.489004 whilet he actual return on invested capital holds at  0.247175.  The Chemours Company’s book to market ratio is at 0.198373 while the book to market mean difference is 0.08898. This indicator tells you how a company is currently valued in terms of Book to Market compared to its average Book to Market over the past 10 years. It’s important to note that BM is the inverse of the Price to book ratio. Thus a high BM ratio means a company is undervalued.

In glancing at some key ratios we note that the Piotroski F-Score is at 8 (1 to 10 scale) and the ERP5 rank is at 5289. The Q.I. Value of The Chemours Company (NYSE:CC) currently reads 11.00000 on the Quant scale. The Free Cash Flow score of 1.707370 is also swinging some momentum at investors. The United States of America based firm is currently valued at 54188.

Some other notable ratios include the Accrual Ratio of 0.082101, the Altman Z score of 2.536156, a Montier C-Score of 2.00000 and a Value Composite rank of 20.

Debt

In looking at some Debt ratios, The Chemours Company (NYSE:CC) currently has a debt to equity ratio of 3.50789 and a Free Cash Flow to Debt ratio of 0.168542. This ratio gives insight as to how high the firm’s total debt is compared to its free cash flow generated. In terms of Net Debt to EBIT, that ratio stands at 1.97678. This ratio reveals how easily a firm is able to pay interest and capital on its net outstanding debt. The lower the ratio the better as that indicates that the company is able to meet its interest and capital payments. Lastly we’ll take note of the Net Debt to Market Value ratio. The Chemours Company’s ND to MV current stands at 0.474008. This ratio is calculated as follows: Net debt (Total debt minus Cash ) / Market value of the company.

As most investors know, the stock market can be a highly volatile place. Investors often have to figure out a way that they can personally stay on track so they don’t veer of course. Sticking to a well-researched trading strategy may work for some people. Others may jump into the market head first without too much planning and hope to gain profits by learning as they go. The stock market learning curve may be vastly different for individuals depending on their circumstances and backgrounds. What’s good for one person may not be good for another. When the markets are rising steadily and running along smoothly, investors may feel like they can do no wrong when it comes to picking stocks. People who become overconfident in their abilities may be faced with a harsh reality when the market shifts and momentum builds to the downside. Investors who are prepared for any economic situation might be able to much better ride out the storm when the time comes.  

The Chemours Company (NYSE:CC) are showing an adjusted slope average of the past 125 and 250 days of -49.15763.  The Adjusted Slope 125/250d indicator is equal to the average annualized exponential regression slope, over the past 125 and 250 trading days, multiplied by the coefficient of determination (R2).  The purpose of this calculation is to provide a longer term average adjusted slope value that levels out large share price movements by using the average. This indicator is useful in helping find stocks that have been on a smooth upward trend over the past 6 months to a year.

Drilling down into some additional key near-term indicators we note that the Capex to PPE ratio stands at 0.158715 for The Chemours Company (NYSE:CC).  The Capex to PPE ratio shows you how capital intensive a company is. Stocks with an increasing (year over year) ratio may be moving to be more capital intensive and often underperform the market. Higher Capex also often means lower Free Cash Flow (Operating cash flow – Capex) generation and lower dividends as companies don’t have the cash to pay dividends if they are investing more in the business.

Some investors may succeed spectacularly in the market while others fail. There is an emotional component to trading and investing which can pose a big obstacle to trading success. Investors frequently try to optimize every decision for success, but sometimes things just don’t work out as planned. Consistently beating the market may involve heavy amounts of homework, and a necessary rebalancing of the portfolio. In fast paced markets, indecision can have a drastic impact. Investors may have all the bases covered but fail to make a trade based only on the fear of being wrong. Individual investors may need to conquer self-doubt in order to reach optimal performance when picking stocks. This may not come as easily for some as it does for others. When the market is winning, investors may become too complacent given the ease of gains. Staying on top of the investing scene even when everything is good may help to prepare if conditions change and the climate starts to worsen.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.